Yes agree, I’m reasonably familiar with the distinctions, ESPAC group in UK has recently presented some results for BR after pre op therapy, they used accepted NCCN criteria to define BR to ensure consistency.
I think Panco study left it to sites to decide, therefore not standardised. The point of all this is company has made repeated statements that all the patients resected in trial were truly non- resectable, but I think that’s inaccurate.
they’ve reported R0 before, they say 8 of the 10 resections were R0 but unless they do independent retro review of pre treatment CTs to see who was BR, who was unresectable (by an accepted standard like NCN) it’ll be difficult to answer your question about any R0 in truly unresectable cases. At present company seems to be reporting the entire cohort as unresectable LAPC, no mention of BR anywhere.
- Forums
- ASX - By Stock
- OSL
- OSL Top Pick for FY21
OSL Top Pick for FY21, page-14
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
|
|||||
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $43.51M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $111.8K | 10.17M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 300000 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 7793598 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 300000 | 0.011 |
10 | 8320000 | 0.010 |
22 | 14670708 | 0.009 |
6 | 5693850 | 0.008 |
14 | 5041677 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 7793598 | 12 |
0.013 | 13031397 | 8 |
0.014 | 7136450 | 10 |
0.015 | 10079912 | 5 |
0.016 | 4641791 | 4 |
Last trade - 11.50am 15/08/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online